Zimmer Biomet (ZBH) Given “Hold” Rating at Canaccord Genuity

Zimmer Biomet (NYSE:ZBH)‘s stock had its “hold” rating reiterated by stock analysts at Canaccord Genuity in a note issued to investors on Friday. They presently have a $132.00 price target on the medical equipment provider’s stock. Canaccord Genuity’s price objective indicates a potential upside of 5.82% from the stock’s current price.

Several other research analysts also recently weighed in on ZBH. Zacks Investment Research upgraded shares of Zimmer Biomet from a “sell” rating to a “hold” rating in a research report on Tuesday, September 26th. SunTrust Banks reiterated a “buy” rating and issued a $136.00 price target on shares of Zimmer Biomet in a research report on Monday, October 2nd. Piper Jaffray Companies downgraded shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating in a research report on Thursday, November 2nd. BMO Capital Markets decreased their price target on shares of Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating on the stock in a research report on Thursday, November 2nd. Finally, Morgan Stanley decreased their price target on shares of Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating on the stock in a research report on Thursday, November 2nd. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet currently has an average rating of “Buy” and a consensus price target of $137.25.

Zimmer Biomet (NYSE:ZBH) traded down $0.18 on Friday, reaching $124.74. 1,073,100 shares of the company’s stock traded hands, compared to its average volume of 1,389,300. The company has a quick ratio of 0.78, a current ratio of 1.47 and a debt-to-equity ratio of 0.88. Zimmer Biomet has a fifty-two week low of $103.62 and a fifty-two week high of $133.49. The company has a market capitalization of $25,260.00, a P/E ratio of 38.86, a PEG ratio of 1.94 and a beta of 1.15.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet had a return on equity of 16.29% and a net margin of 8.36%. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.83 billion. During the same quarter in the previous year, the business posted $1.79 earnings per share. The firm’s revenue was down .8% on a year-over-year basis. research analysts expect that Zimmer Biomet will post 8.03 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the company. CWA Asset Management Group LLC increased its holdings in Zimmer Biomet by 1.8% in the 2nd quarter. CWA Asset Management Group LLC now owns 1,952 shares of the medical equipment provider’s stock valued at $251,000 after acquiring an additional 34 shares during the last quarter. Advisory Services Network LLC increased its holdings in Zimmer Biomet by 1.0% in the 2nd quarter. Advisory Services Network LLC now owns 3,690 shares of the medical equipment provider’s stock valued at $474,000 after acquiring an additional 37 shares during the last quarter. Sandy Spring Bank increased its holdings in Zimmer Biomet by 5.4% in the 2nd quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock valued at $166,000 after acquiring an additional 66 shares during the last quarter. Financial Counselors Inc. increased its holdings in Zimmer Biomet by 1.2% in the 2nd quarter. Financial Counselors Inc. now owns 6,215 shares of the medical equipment provider’s stock valued at $798,000 after acquiring an additional 73 shares during the last quarter. Finally, Synovus Financial Corp increased its holdings in Zimmer Biomet by 6.3% in the 2nd quarter. Synovus Financial Corp now owns 2,288 shares of the medical equipment provider’s stock valued at $293,000 after acquiring an additional 135 shares during the last quarter. Hedge funds and other institutional investors own 85.92% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Zimmer Biomet (ZBH) Given “Hold” Rating at Canaccord Genuity” was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2018/01/05/zimmer-biomet-zbh-given-hold-rating-at-canaccord-genuity.html.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit